title: Introduction: Perampanel--new mode of action and new option for patients with epilepsy.
abstract: With perampanel the first-in-class selective alpha-amino-3-hydroxy-5-methyl-4-isoxazolprepionic acid (AMPA) receptor antagonist has been finally approved for add-on treatment in patients with focal-onset seizures. This suggests additional therapeutic potential in hitherto difficult-to-treat epilepsies.
authors.affiliation: Kork Epilepsy Center, Kehl-Kork, Germany.
authors.forename: Bernhard J
authors.initials: BJ
authors.lastname: Steinhoff
mesh_terms: D000927:Anticonvulsants / Q000627:therapeutic use*; D004827:Epilepsy / Q000188:drug therapy*; D006801:Humans; D009570:Nitriles; D011728:Pyridones / Q000627:therapeutic use*; D018091:Receptors, AMPA / Q000037:antagonists & inhibitors*
chemical_list: D000927:Anticonvulsants; D009570:Nitriles; D011728:Pyridones; D018091:Receptors, AMPA; C551441:perampanel
keywords: Antiepileptic drugs; Glutamate; Mode of action; Perampanel